Omnia Ahmed: Effect of Hematocrit (HCT) on Coagulation Testing
Omnia Ahmed, Laboratory Technologist at Faculty of Medical Laboratory Sciences at University of Gezira, shared a post on LinkedIn:
”Effect of Hematocrit (HCT) on Coagulation Testing
What is HCT?
Hematocrit (HCT) is the percentage of whole blood volume occupied by red blood cells (RBCs).
When is HCT increased or decreased?
High HCT: Increased RBC volume
Can be seen in conditions such as dehydration, chronic hypoxia, smoking, or polycythemia.
Low HCT: Decreased RBC volume
Can occur due to blood loss, iron deficiency, nutritional deficiencies, chronic disease, or other causes of anemia.
How does this affect coagulation tests?
Assuming the blood volume was collected correctly, coagulation tubes normally maintain a 9:1 blood-to-sodium citrate ratio.
High HCT (Falsely Prolonged Result):
High HCT means more RBCs and less plasma. Therefore, the fixed amount of citrate becomes excessive relative to the plasma volume.
When calcium reagent is added during the test, the excess citrate can chelate more calcium, leaving less calcium available for coagulation.
Result: Falsely prolonged PT/aPTT.
Low HCT (Potentially Falsely Shortened Result):
Low HCT means fewer RBCs and more plasma. This changes the citrate-to-plasma relationship.
When calcium reagent is added, the altered citrate/plasma ratio can result in greater effective calcium availability, potentially accelerating clot formation.
Result: Potentially falsely shortened PT/aPTT.
Key Point:
The problem is not necessarily incorrect blood collection. The issue is the altered plasma-to-citrate ratio caused by an abnormal HCT.
What should we do?
When HCT is significantly abnormal, particularly greater than 55 percent, the citrate volume should be corrected according to the patient’s HCT to maintain the appropriate blood-to-anticoagulant ratio.
Therefore, HCT correction is important to obtain accurate coagulation results and avoid preanalytical errors.”
Stay updated with Hemostasis Today.
-
Sep 2, 2026, 18:26Strengthening Comprehensive Care for Inherited Bleeding Disorders in Ecuador – World Federation of Hemophilia
-
Sep 2, 2026, 18:24Zeeshan Ahmed Khattak: Managing Febrile Neutropenia in Hematology/Oncology and Transplant Patients
-
Sep 2, 2026, 18:22Mark Heyland: The Role of Thromboinflammation in Fracture Non-Union
-
Sep 2, 2026, 18:18Katie Gonzalez: Understanding the Hidden Risk of Inherited Thrombophilias
-
Sep 2, 2026, 18:14Beruni Narmada W: Rare Basal Vein of Rosenthal Thrombosis Presenting With Thalamic Haemorrhage
-
Sep 2, 2026, 17:44John Thymis: Five E-Posters Presented at ESC Congress 2026 in Munich
-
Sep 2, 2026, 17:42Edward Lee Carter: In Antithrombotic Therapy, “More Protection” Can Become More Harm Surprisingly Quickly
-
Sep 2, 2026, 17:41Mohsin Raza: Why Is Anticoagulation Used During Hemodialysis?
-
Sep 2, 2026, 17:37Hilaryano Ferreira: Presented Our Meta-Analysis of LAAC Versus Oral Anticoagulation at ESC Congress